Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF FINANCIAL OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 20,854 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,694 · Balance 18,848 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,750 · Balance 20,598 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,591 · Balance 22,189 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 3,069 · Balance 25,258 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,404 · Balance 20,854 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,800 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 7,800 · Balance 7,800 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 9,206 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 3,069 · Balance 9,206 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,182 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,591 · Balance 3,182 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,750 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,750 · Balance 1,750 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,694 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 31,150 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 31,150 · Balance 31,150 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2024 Filed Apr 8, 2024 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010509 · form4-04082024_090417.xml · derivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,615 Underlying: Class A Common Share · 6,365 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date April 1, 2024. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date April 1, 2024. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 5,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010509 · form4-04082024_090417.xml · derivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,092 Underlying: Class A Common Share · 5,092 shares Expires 2034-03-31 F3 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Common Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F4 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Common Share of the Issuer no later than January 30, 2027, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 33,150 | $0.00 Strike: $18.06 | $0.00 |
DisclosureSEC source: 0001415889-24-010509 · form4-04082024_090417.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,150 Underlying: Class A Common Share · 33,150 shares Expires 2034-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010091 · form4-04032024_090446.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 Underlying: Class A Common Share · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 514 | $19.70 | $10,125.80 |
DisclosureSEC source: 0001415889-24-010091 · form4-04032024_090446.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,868 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010091 · form4-04032024_090446.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 12,000 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001415889-24-000609 · form4-01042024_040113.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 12,000 shares Expires 2029-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 12,000 | $20.00 | $240,000.00 |
DisclosureSEC source: 0001415889-24-000609 · form4-01042024_040113.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,632 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 21:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 12,000 | $8.83 | $105,960.00 |
DisclosureSEC source: 0001415889-24-000609 · form4-01042024_040113.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013042 · form4-09062023_110953.xml · derivative · entry 8 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,722 Underlying: Class A Common Share · 1,861 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 547 | $17.76 | $9,714.72 |
DisclosureSEC source: 0001415889-23-013042 · form4-09062023_110953.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,632 Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013042 · form4-09062023_110953.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 42,050 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001415889-23-013042 · form4-09062023_110953.xml · derivative · entry 7 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,050 Underlying: Class A Common Share · 42,050 shares Expires not disclosed F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. F4 · derivative.expiration_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013042 · form4-09062023_110953.xml · derivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Class A Common Share · 7,000 shares Expires 2033-08-31 F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013042 · form4-09062023_110953.xml · derivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,082 Underlying: Class A Common Share · 2,695 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 791 | $17.76 | $14,048.16 |
DisclosureSEC source: 0001415889-23-013042 · form4-09062023_110953.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,318 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013042 · form4-09062023_110953.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007004 · form4-04282023_040401.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,981 Underlying: Class A Common Share · 990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 291 | $11.15 | $3,244.65 |
DisclosureSEC source: 0001415889-23-007004 · form4-04282023_040401.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,414 Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-007004 · form4-04282023_040401.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-006441 · form4-04112023_090443.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,082 Underlying: Class A Common Share · 2,695 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 791 | $10.71 | $8,471.61 |
DisclosureSEC source: 0001415889-23-006441 · form4-04112023_090443.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,715 Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-006441 · form4-04112023_090443.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005789 · form4-04032023_040415.xml · derivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Class A Common Share · 7,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 42,050 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001415889-23-005789 · form4-04032023_040415.xml · derivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,050 Underlying: Class A Common Share · 42,050 shares Expires 2033-03-31 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2023. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005230 · form4-03202023_090333.xml · derivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 2,158 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. F3 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 634 | $11.12 | $7,050.08 |
DisclosureSEC source: 0001415889-23-005230 · form4-03202023_090333.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,811 Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,158 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005230 · form4-03202023_090333.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 872 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005230 · form4-03202023_090333.xml · derivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,744 Underlying: Class A Common Share · 872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 256 | $11.46 | $2,933.76 |
DisclosureSEC source: 0001415889-23-005230 · form4-03202023_090333.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,287 Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005230 · form4-03202023_090333.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009348 · form4-09062022_010947.xml · derivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,583 Underlying: Class A Common Share · 1,861 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 547 | $11.44 | $6,257.68 |
DisclosureSEC source: 0001415889-22-009348 · form4-09062022_010947.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,671 Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-009348 · form4-09062022_010947.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 10,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009348 · form4-09062022_010947.xml · derivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,777 Underlying: Class A Common Share · 10,777 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:10 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 64,660 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001415889-22-009348 · form4-09062022_010947.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,660 Underlying: Class A Common Share · 64,660 shares Expires 2032-08-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 991 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004316 · form4-04282022_040401.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,971 Underlying: Class A Common Share · 991 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 282 | $9.99 | $2,817.18 |
DisclosureSEC source: 0001415889-22-004316 · form4-04282022_040401.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,357 Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 991 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-004316 · form4-04282022_040401.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 10,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003990 · form4-04112022_040401.xml · derivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,777 Underlying: Class A Common Share · 10,777 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 64,660 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-22-003990 · form4-04112022_040401.xml · derivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,660 Underlying: Class A Common Share · 64,660 shares Expires 2032-04-06 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003284 · form4-03232022_040315.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 3,019 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,047 | $10.98 | $11,496.06 |
DisclosureSEC source: 0001415889-22-003284 · form4-03232022_040315.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,648 Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 3,019 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-003284 · form4-03232022_040315.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 872 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002325 · edgar.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,616 Underlying: Class A Common Share · 872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 303 | $10.13 | $3,069.39 |
DisclosureSEC source: 0001179110-22-002325 · edgar.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,676 Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-002325 · edgar.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 7,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008653 · edgar.xml · derivative · entry 2 Ragosa Mark · CIK 0001835458 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,444 Underlying: Class A Common Shares · 7,444 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 44,661 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001179110-21-008653 · edgar.xml · derivative · entry 1 Ragosa Mark · CIK 0001835458 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,661 Underlying: Class A Common Shares · 44,661 shares Expires 2031-09-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004651 · edgar.xml · derivative · entry 2 Ragosa Mark · CIK 0001835458 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,962 Underlying: Class A Common Shares · 3,962 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.